Year: 2015
Type: article
Abstract: Fecal microbiota transplant (FMT) research trials are growing in diverse intestinal and extraintestinal conditions that are thought to be either caused or correlated with gut microbiota dysbiosis. Although, the mechanism by which the microbiota results in disease initiation or progression is not fully understood, it is speculated that restoring the symbiosis by FMT could have therapeutic benefits. FMT is currently approved by the US Food and Drug Administration (FDA) for the treatment of recurrent pseudomembranous colitis caused by Clostridium difficile; which is a direct consequence of alteration in microbiota composition caused by long-term antibiotics consumption. Because the disease is directly linked to an altered microbiota compo-sition, it is intuitive that restoring the normal composition-by using non-stringent criteria to define ‘normal’- will alter the niche in a way that the commensals will outcompete C. difficile bacteria and hence, the infection will be controlled in an ecological manner.1
Source: PubMed Central
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W1833129605